Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck’s Molnupiravir Set To Lead Forecast $6bn COVID-19 Oral Antiviral Market

Pfizer and Roche Also In The Running

Executive Summary

Merck’s antiviral could play a big role, but only if it proves effective in broader settings, such as post-exposure prophylaxis.

You may also be interested in...



Could Prevention Data Give REGEN-COV Competitive Leg Up?

Could Prevention Data Give REGEN-COV Competitive Leg Up?

Pfizer’s Oral COVID-19 Pill Paxlovid Tops Merck’s Molnupiravir

Pfizer reported its protease inhibitor Paxlovid showed an 89% risk reduction for hospitalization and death compared to placebo in interim results of a Phase II/III trial. The pharma now is seeking a quick EUA in the US.

Merck Forecasts Global Molnupiravir Revenues Of $5bn-$7bn Through 2022

Assuming emergency use authorization of the antiviral to fight COVID-19 in December, Merck expects to make $500m-$1bn this year. It will share profits equally with partner Ridgeback.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC145189

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel